BlackRock’s Whitehawk Therapeutics WHWK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $8.81M | Buy |
1,922,828
+1,571,443
| +447% | +$6.54M | ﹤0.01% | 3732 |
|
|
2026
Q1 | $1.21M | Buy |
351,385
+52,374
| +18% | +$164K | ﹤0.01% | 4269 |
|
|
2025
Q4 | $724K | Buy |
299,011
+2,853
| +1% | +$6.55K | ﹤0.01% | 4395 |
|
|
2025
Q3 | $563K | Sell |
296,158
-2,162
| -0.7% | -$3.98K | ﹤0.01% | 4430 |
|
|
2025
Q2 | $558K | Buy |
298,320
+57,071
| +24% | +$99.3K | ﹤0.01% | 4412 |
|
|
2025
Q1 | $429K | Sell |
241,249
-2,641
| -1% | -$6.9K | ﹤0.01% | 4437 |
|
|
2024
Q4 | $769K | Buy |
243,890
+1,002
| +0.4% | +$2.27K | ﹤0.01% | 4294 |
|
|
2024
Q3 | $500K | Sell |
242,888
-77,359
| -24% | -$125K | ﹤0.01% | 4328 |
|
|
2024
Q2 | $468K | Sell |
320,247
-720,759
| -69% | -$1.34M | ﹤0.01% | 4361 |
|
|
2024
Q1 | $2.44M | Sell |
1,041,006
-40,625
| -4% | -$78.3K | ﹤0.01% | 3937 |
|
|
2023
Q4 | $2.18M | Buy |
1,081,631
+75,825
| +8% | +$318K | ﹤0.01% | 4009 |
|
|
2023
Q3 | $4.87M | Sell |
1,005,806
-11,318
| -1% | -$65.8K | ﹤0.01% | 3667 |
|
|
2023
Q2 | $6.96M | Buy |
1,017,124
+140,959
| +16% | +$1.1M | ﹤0.01% | 3580 |
|
|
2023
Q1 | $6.34M | Sell |
876,165
-15,698
| -2% | -$168K | ﹤0.01% | 3531 |
|
|
2022
Q4 | $11.4M | Buy |
891,863
+33,361
| +4% | +$436K | ﹤0.01% | 3334 |
|
|
2022
Q3 | $12.1M | Sell |
858,502
-44,175
| -5% | -$581K | ﹤0.01% | 3321 |
|
|
2022
Q2 | $11.1M | Buy |
902,677
+592,550
| +191% | +$8.8M | ﹤0.01% | 3450 |
|
|
2022
Q1 | $5.26M | Buy |
310,127
+573
| +0.2% | +$11K | ﹤0.01% | 3928 |
|
|
2021
Q4 | $7.48M | Buy |
309,554
+293,304
| +1,805% | +$7.37M | ﹤0.01% | 3822 |
|
|
2021
Q3 | $478K | Buy |
16,250
+177
| +1% | +$5.4K | ﹤0.01% | 4767 |
|
|
2021
Q2 | $407K | Buy |
16,073
+7,715
| +92% | +$176K | ﹤0.01% | 4745 |
|
|
2021
Q1 | $162K | Buy |
8,358
+465
| +6% | +$10.7K | ﹤0.01% | 4773 |
|
|
2020
Q4 | $116K | Buy |
7,893
+272
| +4% | +$5.82K | ﹤0.01% | 4556 |
|
|
2020
Q3 | $171K | Buy |
7,621
+3
| +0% | +$63 | ﹤0.01% | 4433 |
|
|
2020
Q2 | $143K | Sell |
7,618
-4,125
| -35% | -$54K | ﹤0.01% | 4433 |
|
|
2020
Q1 | $97K | Buy |
11,743
+420
| +4% | +$3.87K | ﹤0.01% | 4357 |
|
|
2019
Q4 | $106K | Buy |
11,323
+96
| +0.9% | +$800 | ﹤0.01% | 4440 |
|
|
2019
Q3 | $114K | Buy |
11,227
+212
| +2% | +$2.35K | ﹤0.01% | 4424 |
|
|
2019
Q2 | $150K | Buy |
11,015
+4,853
| +79% | +$73.6K | ﹤0.01% | 4406 |
|
|
2019
Q1 | $83K | Buy |
+6,162
| New | +$265K | ﹤0.01% | 4403 |
|
Other funds holding WHWK
YF
SL
BlackRock's WHWK Position: Q2 2026 in Review
BlackRock increased its Whitehawk Therapeutics (WHWK) stake by 447% in Q2 2026, buying an estimated $6.54M and bringing the position to 1,922,828 shares worth $8.81M. The position accounts for ﹤0.01% of the portfolio, ranked #3732.
BlackRock first reported a position in WHWK in Q1 2019 and has held it in 30 quarters since. The position peaked at $12.1M in Q3 2022. 77 funds tracked by Wall St. Rank hold WHWK as of Q2 2026.
- BlackRock held 1,922,828 shares of Whitehawk Therapeutics worth $8.81M as of Q2 2026.
- BlackRock bought 1,571,443 Whitehawk Therapeutics shares in Q2 2026, an estimated $6.54M.
- Whitehawk Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #3732 holding.
- BlackRock first reported a position in Whitehawk Therapeutics in Q1 2019 and has held it in 30 quarters since.
- BlackRock's Whitehawk Therapeutics position peaked at $12.1M in Q3 2022.
- 77 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q2 2026.
Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.